Back to Search Start Over

Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs

Authors :
Andrew D. Mosholder
Justin Mathew
Sumathi Nambiar
Harry Smith
John J. Alexander
Source :
New England Journal of Medicine. 368:1665-1668
Publication Year :
2013
Publisher :
Massachusetts Medical Society, 2013.

Abstract

The FDA recently approved labeling changes advising against the use of azithromycin in patients with known cardiovascular risk factors such as QT-interval prolongation, hypokalemia, hypomagnesemia, bradycardia, or use of class IA or class III antiarrhythmic agents.

Subjects

Subjects :
Bradycardia
medicine.medical_specialty
business.industry
Cardiovascular risk factors
General Medicine
Pharmacology
Azithromycin
medicine.disease
Hypokalemia
Class iii antiarrhythmic
Hypomagnesemia
Internal medicine
Medicine
In patient
medicine.symptom
business
medicine.drug

Details

ISSN :
15334406 and 00284793
Volume :
368
Database :
OpenAIRE
Journal :
New England Journal of Medicine
Accession number :
edsair.doi...........e616ea50ba475477832b6511bc2d9d50
Full Text :
https://doi.org/10.1056/nejmp1302726
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details